PORT-OF-SPAIN, Trinidad (CMC):Test captain Jason Holder says the standard of regional pitches needs to be improved if teams are to produce more attractive cricket.The 24-year-old, also the Barbados Pride skipper, said that scores in the ongoing Regional Super50 had been low because pitches were slow and turning and not conducive to good strokeplay.”It’s been tough. Obviously, the scores are not what we’ve been accustomed to in one-day cricket, and I think that’s been due to the slow pitches,” Holder said.”I’ve found it very difficult so far batting in this tournament, in the middle overs especially, and trying to get the ball off the square. I think spinners are dominating it, and that’s because the ball has spun quite early and quite sharply.”I just think we need to work a little bit more on improving our pitches and … strokeplay, and the viewing of the cricket would be a lot better.”The highest total of the tournament has been Jamaica Scorpions’ 260 against minnows ICC Americas at the Sir Frank Worrell ground at St Augustine here in the second-round Group ‘A’ contest.In Group ‘B’ played in St Kitts, the highest total there was 255 by Guyana Jaguars in the final round when they chased down a competitive total set by Combined Campuses and Colleges Marooners.Between both groups, there have been 14 totals under 200 runs, with four of these coming at Queen’s Park Oval, and Holder said that the par score at the tournament’s premier venue would be quite small.”It’s been a tough pitch. The games I’ve seen here and have played here have been tough going in terms of batting, so you have to be very sharp in the field in terms of restricting opposition under 200 runs. I think 200, 210 is probably a par score on this track.”The tournament is in its final stages. Barbados Pride clash with Windward Islands Volcanoes in the second semi-final today.
COLUMBUS, Ohio — The Erik Karlsson injury watch resumed in Columbus on Saturday.Karlsson left the ice midway through the Sharks 4-0 loss to the Columbus Blue Jackets after re-aggravating his injured groin, missing the game’s last 33:04.The two-time Norris Trophy winner suited up for his fourth straight game Saturday after missing nine games with a groin injury. Head coach Pete DeBoer initially labeled the injury as “not serious” after he held Karlsson off the ice for most of the third period …
CLICK HERE if you are having a problem viewing the photos or video on a mobile deviceOnce again this postseason, it seems everyone is angry except for the Sharks and their fans after their 5-4 overtime win over the St. Louis Blues in Game 3 of the Western Conference final.In the Vegas series, it was the penalty that led to four Game 7 power play goals. Against Colorado, it was a challenged offside call that negated a key Game 7 goal. This time, it appears the officials missed a handpass …
SALT LAKE CITY — Warriors center Marquese Chriss grimaced as he grabbed his leg, but he and the Warriors did not want an opportunity to earn a rare win slip away because of a banged knee.A collision with Jazz guard Emmanuel Mudiay sent Chriss limping to the locker room with a left knee contusion. Shortly after, Chriss checked back into the game. The Warriors (5-22) lost to the Jazz 114-106 Friday at Vivint Smart Home Arena, but not without showing the kind of grit they’ve grown accustomed …
TagsTransfersAbout the authorPaul VegasShare the loveHave your say New Nice owner Ratcliffe remains interested buying Premier League clubby Paul Vegasa month agoSend to a friendShare the loveNew Nice owner Sir Jim Ratcliffe remains interested in buying a Premier League club.It’s understood he looked at Newcastle and Chelsea this year – and he may return to buy a top flight club at a later date, says the Mirror.Those close to the man, who started life in a council house in Greater Manchester, insist they haven’t ruled out Ratcliffe making a Premier League impact one day.A business confidante said: “Jim was genuinely interested in buying a leading Premier League club. At the same time he wants value for money and after considering the cost involved and the necessary investment he chose Nice ahead of Premier League clubs he was in negotiations with.”
About the authorFreddie TaylorShare the loveHave your say Chelsea manager Lampard positive Kante will face Lilleby Freddie Taylor24 days agoSend to a friendShare the loveChelsea manager Frank Lampard has confirmed N’Golo Kante is a chance to face Lille in the Champions League on Wednesday night.Injuries have disrupted Kante all season, with a hamstring niggle the latest ailment that caused him to miss Saturday’s win over Brighton.But the World Cup winner returned to training on Tuesday and Lampard was confident he could play against the Ligue 1 outfit.”He trained this morning and he got through training okay,” said Lampard.”He is still one we have to assess in the morning but we are positive he will be fit to play.”The injury doesn’t relate to the Europa League final. What that injury did do, regardless of whether he played that game, was meant he had a broken pre-season.”It’s a slight domino effect. The main injury is now feeling good, but he’s probably got a couple of niggles since that, and a tackle at Manchester United in the first game that affected him on the ankle.”There’s a bit of bad luck in there as well. Everyone is working towards getting him regularly fit so he can play continuous games, and I’m hoping that’s coming really soon.”
About the authorFreddie TaylorShare the loveHave your say Mourinho adamant about Man Utd striker Rashford: He’s not a target manby Freddie Taylor5 days agoSend to a friendShare the loveFormer Manchester United manager Jose Mourinho is adamant Marcus Rashford is not a target man.Mourinho was speaking after Rashford scored in United’s 1-1 draw with Liverpool on Sunday.”When we beat Liverpool a couple of years ago, we played with Rashford and Romelu Lukaku up front. He is not a target man, he is a man of movement,” Mourinho told Sky Sports.”I do not think he is a pure nine. If Ole is going to play him as he did today then I think he is the perfect player for him.”He’s young but he is experienced. With 21 years he probably has more matches than some players who are 24, 25. For me he is potentially a very good player, in some models and in some positions.”As a number nine I don’t think he has the 30 goals a season in him. I don’t think he can get better as a target man. To be better as a target man is difficult for him.”
Reviewed by James Ives, M.Psych. (Editor)Feb 8 2019Scientists from ITMO in collaboration with their international colleagues proposed new DNA-based nanomachines that can be used for gene therapy of cancer. This new invention can greatly contribute to making the treatment of oncological diseases more effective and selective. The results were published in Angewandte Chemie.Gene therapy is considered one of the promising ways of treating oncological diseases, even though the current approaches are far from perfect. Oftentimes, the agents fail to discern malignant cells from healthy ones, and are bad at interacting with folded RNA targets.In order to solve this issue, scientists, including a Russian team from ITMO University headed by professor Dmitry Kolpashchikov, proposed special nanomachines. Their operation principle is based on using particular molecules, deoxyribozymes, which can interact with targeted RNA, bind them, unfold and cleave. According to the scientists’ idea, these nanomachines have to recognize DNA oncomarkers and form complexes that can break down messenger RNA of vital genes with high selectivity, which will then result in apoptotic death of malignant cells.Related StoriesStudy reveals link between inflammatory diet and colorectal cancer riskHow cell-free DNA can be targeted to prevent spread of tumorsStudy: Nearly a quarter of low-risk thyroid cancer patients receive more treatment than necessaryThe researchers have tested the efficiency of the new machines in a model experiment and learned that they can cleave folded RNA molecules better than the original deoxyribozymes. They showed that the design of the nanomachine makes it possible to break down targeted RNA in the presence of a DNA oncomarker only, and the use of RNA-unfolding arms provides for the machine’s better efficiency. The scientists also learned that the nanomachine can inhibit the growth of malignant cells, though cellular experiments didn’t show high specificity. The researchers associate such a result with a possibly poor choice of the RNA target and a low stability of DNA structures in the cell.The new approach differs fundamentally from the ones used before. The existing gene therapy agents are aimed at suppressing the expression of oncological markers. In the research in question, the scientists focused on the messenger RNA of vital genes, and the oncological marker was used as an activator. This makes it possible to apply the DNA nanomachine in treating any kind of cancer by using new DNA oncomarkers for activating the breaking down of targeted molecules.The new invention opens new ways of treating oncological diseases. Still, there are many experiments to be conducted before it can be applied in therapy.”For now, we are trying to introduce new functional elements in the framework, ones that will contribute to a more effective recognition of oncological markers, and are also optimizing the DNA nanomachine for various RNA targets. In order to improve the efficiency and selectiveness of our constructions in cellular conditions, we are selecting new RNA targets and studying the stability of DNA machines in cells, which we plan to improve with the help of the already existing chemical modifications,” comments Daria Nedorezova, Master’s student at ITMO University. Source:http://en.ifmo.ru/
Source:https://www.gu.se/english/about_the_university/news-calendar/News_detail//low-adherence-to-cholesterol-lowering-medication-also-protective-in-type-2-diabetes.cid1619723 Reviewed by James Ives, M.Psych. (Editor)Mar 9 2019Type 2 diabetes patients’ risk of cardiovascular disease and death decreases if they actually take the cholesterol-lowering drugs as prescribed. However, research shows that the risk is also reduced if they do not take the full dosage.”These results are important and useful for patients and healthcare providers alike, to try and motivate patients to follow the recommended treatment even if they forget to take their pills from time to time,” notes Sofia Karlsson, Postdoctoral Researcher in Pharmacy at Sahlgrenska Academy, University of Gothenburg.The purpose of her thesis was to investigate the risk of cardiovascular disease and death in relation to prescription and use of cholesterol-lowering drugs among adults with type 2 diabetes.Related StoriesDiabetes patients experiencing empathy from PCPs have beneficial long-term clinical outcomesSome people treated for type 1 diabetes may have monogenic diabetes, study findsIntermittent fasting may protect against type 2 diabetesThe research builds on register-based studies of adults with type 2 diabetes included in the Swedish National Diabetes Register. Prescription of cholesterol-lowering drugs for these patients was estimated from data entered in the Register. The patients’ adherence to medications was estimated on the basis of information of filled prescriptions at pharmacies.One in four stopped to collectThe results show that, on average, patients had cholesterol-lowering drugs available for some 70 percent of the three-year study period. The prescription process may partly explain why this proportion was not 100 percent, and the fact is that one in four patients who started to collect the medication stopped filling their prescriptions as early as within the first year.During the second year, the proportion of patients who stopped filling their prescriptions dropped to 13 percent, and during the third year the number decreased to 5 percent. Patients with previous cardiovascular disease showed slightly higher adherence than those without prior cardiovascular disease.Karlsson’s thesis is based on studies covering some 100,000 patients. It confirms previous research showing that the risk of cardiovascular disease and death for patients with type 2 diabetes who adhere well to their cholesterol-lowering drug prescriptions is lower than for patients with poor adherence.Fewer doses also beneficialWhat is new is that the researchers were able to observe a gradual increasing risk of cardiovascular disease with decreasing adherence, which suggests that patients who take their medication to a lesser extent than the doctor recommended, too, experience a beneficial effect. This applies to patients with and without prior cardiovascular disease alike.”When we took into account the attending healthcare provider’s adherence with guidelines regarding prescription of cholesterol-lowering drugs, our findings showed that in patients with type 2 diabetes, the patients’ adherence to drug treatment is what appears to have the greatest impact on their risk for cardiovascular disease and death,” Sofia Karlsson says.
Chicago-based Walton Street Capital has hired brokers to put the 20,000-square-foot store on the market for sale, and is expecting offers in the range of $170 million to $175 million, according to people familiar with the plan.The potential sale comes just a few months after Apple CEO Tim Cook attended the Oct. 20 opening of the glassy store along the Chicago River. The store opened about two weeks after Walton Street Capital, a private equity firm led by billionaire Neil Bluhm, bought the property as part of a $360 million deal that also included the adjacent 35-story office building at 401 N. Michigan Ave. The seller was Zeller Realty Group.Walton Street’s decision to sell the store, where Apple has a 15-year lease, was first reported by The Wall Street Journal.Stephen Sotoloff, a Walton Street principal, declined to comment.Walton Street is offering the Apple store individually, or as part of a larger deal of at least $170 million that would include about 11,000 square feet of ground-floor retail in the office building, according to people familiar with the deal. The deal also could include a portion of Pioneer Court plaza in front of the building and a boat dock leased to Shoreline Sightseeing, sources said.Walton Street will continue to own the office building other than the ground floor retail space.An Eastdil Secured team of brokers will market the property to potential buyers.About 7,000 square feet of ground-floor retail space in the office building is leased to Fidelity Investments. About 4,000 square feet of retail space on the building’s north side is vacant.Before moving into the new flagship in October, Apple’s Mag Mile store had been at Michigan Avenue and Huron Street since 2003. That space remains vacant.The new flagship was designed by London-based Foster + Partners. Explore further This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Google buys NYC’s Chelsea Market building for $2.4 bn ©2018 Chicago Tribune Distributed by Tribune Content Agency, LLC. Citation: Apple’s new flagship Chicago store is for sale, and could fetch $170 million or more (2018, March 23) retrieved 18 July 2019 from https://phys.org/news/2018-03-apple-flagship-chicago-sale-million.html Apple’s new flagship store on Michigan Avenue is going up for sale and could fetch at least $170 million.